Business
New Data From iRhythm Reinforce the Utility of Long-Term Ambulatory Cardiac Monitoring for Increased Diagnostic Yield and Improved Diagnostic Accuracy of Actionable Arrhythmias
Clinical studies presented at Heart Rhythm 2023 build on the totality of clinical evidence that continue to highlight the value of iRhythm’s Zio products and
About this update from Irhythm Holdings, Inc.
[{"type":"text","content":"Clinical studies presented at Heart Rhythm 2023 build on the totality of clinical evidence that continue to highlight the value of iRhythm’s Zio products and services across a wide range of patient populations\nSAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today the presentation of four studies at the Heart Rhythm Society’s annual meeting, Heart Rhythm 2023, in New Orleans, LA. These new data reinforce the body of clinical evidence that long-term ambulatory cardiac monitoring of up to 14 days with Zio® XT increases diagnostic yield and improves diagnostic accuracy of ventricular arrhythmias across a wide range of patient populations. These new scientific data from iRhythm build on the totality of clinical evidence – including real-world comparative effectiveness and head-to-head studies – that continue to highlight the value of iRhythm’s Zio products and services. Life-threatening ventricular arrhythmias, specifically ventricular tachycardia and ventricular fibrillation, cause about 300,000 deaths per year in the US and account for almost half of deaths from cardiac causes. Early detection and diagnosis are crucial to treating these arrhythmias and preventing adverse health outcomes. “These studies thematically showcase the value of iRhythm’s Zio products and services — in particular for identifying ventricular arrhythmias for risk stratification and disease management,” said Mintu Turakhia, MD, MAS, iRhythm’s chief medical officer, chief scientific officer and executive vice president, product innovation. “The findings have important clinical and scientific implications, and they further demonstrate the strength of our technology across the complete range of clinical arrhythmias.” Extended Ambulatory ECG Monitoring Enhances Identification of Higher-risk Patients With Hypertrophic Cardiomyopathy The EXAMINE-HCM study found that in patients with hypertrophic cardiomyopathy (HCM) – a disease of the heart affecting 1 in 500 people in the U.S. that can lead to an increased risk of sudden cardiac death – long-term monitoring of up to 14 days with the Zio XT service substantially improves diagnostic yield of non-sustained ventricular tachycardia (NSVT). This may be ...